-
Chinese PD-1 scientist "hero" spectrum. Where did they all go?
Time of Update: 2022-11-01
When the great product PD-1 crossed the sea to China and officially opened the era of China's research on biopharmaceuticals, the scientists behind PD-1 have also become the pioneer representatives o
-
The eighth batch of national varieties of drugs is a big conjecture
Time of Update: 2022-10-31
At present, the competition of PD-1 itself is still very fierce, and there are still a large number of similar drugs that have entered the clinical stage after the price reduction, and such drugs can achieve price formation through market competition, so the industry believes that it is of little significance to be included in the national centralized procurement.
-
From the Roche statement, explore issues related to the protection of intellectual property rights in medicines
Time of Update: 2022-10-31
On October 18, 2022, Roche Pharmaceutical issued a statement on its official account saying [1] that the recently approved generic version of mabasavir by CSPC Ouyi fell within the scope of protection of the original drug patent, calling on all parties not to manufacture, sell or promise to sell related products, and has filed a patent link lawsuit.
-
On the ten-billion-level antidepressant track, Kanghong, Luye, Shiyao, and Dongguang Medicine took the lead in breaking through
Time of Update: 2022-10-31
As we all know, diabetes, tumor, autoimmunity and other hot tracks with huge market space have always been the focus of market attention. However, with the approval of Johnson & Johnson's blockbuster
-
The world's first! Johnson & Johnson BCMA/CD3 bispecific antibody was approved for listing, can "King Fried CP" conquer the 100 billion market?
Time of Update: 2022-10-31
Southwest Securities and other public information on the Internet Johnson & Johnson's Janssen announced that its world's first BCMA/CD3 bispecific antibody teclistamab has been approved by the FDA for the treatment of relapsed or refractory multiple myeloma.
-
Interview with Dr. Liu Shigao Nearly 10 new drugs are under development, with the goal of rewriting tumor immunotherapy, what is the confidence of Hankang Biotechnology?
Time of Update: 2022-10-31
WuXi AppTec Content Team: Looking ahead, what kind of company do you want Hankang Biotech to become?WuXi AppTec Content Team:Dr. Shigao Liu: The core mission of Hankon Biotech includes two aspects: on the one hand, to break through the bottleneck of current tumor immunotherapy and benefit cancer patients around the world by developing cutting-edge multifunctional biological drugs with specially designed molecular configurations; On the other hand, through a unique technology platform, it creates a breakthrough new path for tumor immunotherapy.
-
Fast Follow anxiety! When FIC is "yellow", what is the antidote to fast follow-up?
Time of Update: 2022-10-31
" Indeed, the current follow-up of domestic innovative drugs has shifted from following the research and development of overseas marketed drugs in the past to those FIC drugs that are in the clinical stage or even preclinical research with new targets and new technologies.
-
The NMPA issued 14 relevant responses
Time of Update: 2022-10-31
Encourage the development of oral solvents suitable for temporary deployment 03 Orphan Drug Data Protection 03 Orphan Drug Data Protection Article 34 of the current Regulations for the Implementation of the Drug Administration Law of the People's Republic of China stipulates the protection of data protection for drug trials: a data protection period of 6 years is provided for drugs containing new chemical ingredients.
-
Five clinical cases of failure: luck is always a minority, and misfortune has its own misfortune
Time of Update: 2022-10-31
References: References: References: 1、5 impactful drug trial failures from the last year； pharmavoice 1、5 impactful drug trial failures from the last year； pharmavoice In recent years, the field of research and development of new psychedelics-based drugs for depression has been revitalized, such as Johnson & Johnson's ketamine nasal spray Spravato and Axsome Therapeutics' Auvelity, the latter of which was approved in August as the first fast-acting oral drug for the treatment of major depressive disorder.
-
Domestic CAR-T: Persistence in a long way
Time of Update: 2022-10-31
Recently, Fosun Kite Aquilencel injection for the marketing application of a new indication for adult large B-cell lymphoma that is ineffective in first-line immunochemotherapy or relapses within 12
-
2,810 proprietary Chinese medicines suspended (with list)
Time of Update: 2022-10-31
According to Minenet, on October 19, the Gansu Provincial Public Resources Exchange Center issued a notice saying that 45 drugs from 36 enterprises had recently submitted applications for withdrawal due to production line transformation, rising costs, raw material shortages, and production suspension, which could not guarantee the normal supply of medical institutions in Gansu Province.
-
The API business has brought performance growth to many pharmaceutical companies, which has attracted the efforts of enterprises
Time of Update: 2022-10-31
72% over the same period of the previous year; The net profit attributable to shareholders of listed companies was 108 million yuan, an increase of 44.
72% over the same period of the previous year; The net profit attributable to shareholders of listed companies was 108 million yuan, an increase of 44.
-
The road to the rise of China's innovative drugs: too much Lilly, too few Novo Nordisks
Time of Update: 2022-10-31
Looking back at the rise of overseas big pharmaceutical companies, there are two choices in front of domestic innovative pharmaceutical companies: The first is the "big and complete" model represented by Lilly: from diabetes to tumors to autoimmunity, Lilly has blossomed everywhere; The other is the "specialized and refined" model led by Novo Nordisk: in the 100-year history of Novo Nordisk, it has always been deeply engaged in the field of diabetes.
-
This blockbuster Class 1 new drug is about to be approved, and sales are expected to exceed 2 billion yuan
Time of Update: 2022-10-31
According to the 2021 annual report, Enhua Pharmaceutical currently has more than 70 scientific research projects under research, and invested a total of 402 million yuan in scientific research funds in 2021, an increase of 50.
-
When hot money flows into Chinese medicine
Time of Update: 2022-10-31
The most important reason behind the several soaring secondary markets in a year is that policy support for Chinese medicines has been transmitted to the primary market: in addition to traditional investors (government funds, leading enterprises in Chinese medicine), social capital has also begun to intervene in the research and development of new Chinese medicines.
-
The seventh batch of national procurement is continuing to land, and there are many clear implementation times!
Time of Update: 2022-10-31
The notice clarifies that the agreed procurement volume and procurement cycle of the seventh batch of selected products in the first year shall be determined in accordance with the relevant rules in the "National Centralized Drug Procurement Document" (GY-YD2022-1) issued by the National Joint Procurement Office.
-
Professor Zhou Caicun: Lung cancer treatment and drug development
Time of Update: 2022-10-31
Taking PROTAC technology as an example, new drug developers will design a class of bispecific molecules, one end binds to the disease-causing protein they want to destroy, and the other end binds to the E3 ligase, which plays an important role in the protein degradation process, and the two are connected by a linker.
-
Digitalization is on the rise of the pharmaceutical industry, and domestic and foreign pharmaceutical companies are accelerating their deployment
Time of Update: 2022-10-31
Since 2022, many domestic and foreign pharmaceutical companies have announced that they will cooperate with technology companies and artificial intelligence platforms to accelerate the development of new drugs.
-
First-of-its-kind: GPRC5D CAR-T was granted "orphan drug" designation by the US FDA
Time of Update: 2022-10-31
” About OriCAR-017 About OriCAR-017 OriCAR-017 is one of the core products developed by Primeval based on two independent research and development technology platforms of OriAb and OriCAR, and autologous GPRC5D-targeted chimeric antigen receptor T cell therapy is used for the treatment of relapsed/refractory multiple myeloma (R/R MM).
-
A large number of traditional pharmaceutical companies are testing innovation and making efforts on ADCs and CAR-T
Time of Update: 2022-10-31
It is understood that on September 20 this year, the board of directors of Northeast Pharmaceutical deliberated and passed the "Proposal on the Company's Proposed Establishment of Subsidiaries for Foreign Investment", and agreed that the company should invest 500 million yuan of its own funds to establish a wholly-owned subsidiary, thereby accelerating the implementation of ADC drugs and CAR-T cell therapy technical cooperation projects introduced by agreement with the United States MedAbome.
